HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy

Authors:
Julie Vanderpoel Janssen Scientific Affairs, Horsham, PA

Search for other papers by Julie Vanderpoel in
Current site
Google Scholar
PubMed
Close
 PharmD, MPA
,
Bruno Emond Analysis Group, Inc., Montréal, Québec, Canada

Search for other papers by Bruno Emond in
Current site
Google Scholar
PubMed
Close
 MSc
,
Isabelle Ghelerter Analysis Group, Inc., Montréal, Québec, Canada

Search for other papers by Isabelle Ghelerter in
Current site
Google Scholar
PubMed
Close
 BCom
,
Katherine Milbers Analysis Group, Inc., Montréal, Québec, Canada

Search for other papers by Katherine Milbers in
Current site
Google Scholar
PubMed
Close
 MScPH
,
Marie-Hélène Lafeuille Analysis Group, Inc., Montréal, Québec, Canada

Search for other papers by Marie-Hélène Lafeuille in
Current site
Google Scholar
PubMed
Close
 MA
,
Patrick Lefebvre Analysis Group, Inc., Montréal, Québec, Canada

Search for other papers by Patrick Lefebvre in
Current site
Google Scholar
PubMed
Close
 MA
, and
Lorie A Ellis Janssen Scientific Affairs, Horsham, PA

Search for other papers by Lorie A Ellis in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Corresponding Author: Bruno Emond, MSc
  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 536 294 6
PDF Downloads 0 0 0
EPUB Downloads 0 0 0